The current financial score of Lifecore Biomedical Inc is 7.95. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 34.17M, representing a year-over-year increase of 4.92%, while its net profit experienced a year-over-year increase of 18.11%.
The current valuation score of Lifecore Biomedical Inc is 8.79. Its current P/E ratio is -60.24, which is -155.95% below the recent high of 33.71 and -2.33% above the recent low of -61.64.
The current earnings forecast score of Lifecore Biomedical Inc is 8.00. The average price target is 5.64, with a high of 6.28 and a low of 5.00.
The current price momentum score of Lifecore Biomedical Inc is 6.75. Currently, the stock price is trading between the resistance level at 7.39 and the support level at 4.75, making it suitable for range-bound swing trading.
The current institutional shareholding score of Lifecore Biomedical Inc is 7.00. The latest institutional shareholding proportion is 81.48%, representing a quarter-over-quarter increase of 8.09%.
The current risk assessment score of Lifecore Biomedical Inc is 2.60. The company's beta value is 1.07. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.